Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL.
Journal
Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509
Informations de publication
Date de publication:
11 03 2021
11 03 2021
Historique:
received:
14
05
2020
accepted:
04
09
2020
pubmed:
30
9
2020
medline:
27
7
2021
entrez:
29
9
2020
Statut:
ppublish
Résumé
Chronic lymphocytic leukemia (CLL) is characterized by the existence of subsets of patients with (quasi)identical, stereotyped B-cell receptor (BcR) immunoglobulins. Patients in certain major stereotyped subsets often display remarkably consistent clinicobiological profiles, suggesting that the study of BcR immunoglobulin stereotypy in CLL has important implications for understanding disease pathophysiology and refining clinical decision-making. Nevertheless, several issues remain open, especially pertaining to the actual frequency of BcR immunoglobulin stereotypy and major subsets, as well as the existence of higher-order connections between individual subsets. To address these issues, we investigated clonotypic IGHV-IGHD-IGHJ gene rearrangements in a series of 29 856 patients with CLL, by far the largest series worldwide. We report that the stereotyped fraction of CLL peaks at 41% of the entire cohort and that all 19 previously identified major subsets retained their relative size and ranking, while 10 new ones emerged; overall, major stereotyped subsets had a cumulative frequency of 13.5%. Higher-level relationships were evident between subsets, particularly for major stereotyped subsets with unmutated IGHV genes (U-CLL), for which close relations with other subsets, termed "satellites," were identified. Satellite subsets accounted for 3% of the entire cohort. These results confirm our previous notion that major subsets can be robustly identified and are consistent in relative size, hence representing distinct disease variants amenable to compartmentalized research with the potential of overcoming the pronounced heterogeneity of CLL. Furthermore, the existence of satellite subsets reveals a novel aspect of repertoire restriction with implications for refined molecular classification of CLL.
Identifiants
pubmed: 32992344
pii: S0006-4971(21)00552-8
doi: 10.1182/blood.2020007039
pmc: PMC7976441
doi:
Substances chimiques
Immunoglobulin Heavy Chains
0
Immunoglobulin Variable Region
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1365-1376Subventions
Organisme : NCI NIH HHS
ID : R01 CA238523
Pays : United States
Informations de copyright
© 2021 by The American Society of Hematology.
Références
Nature. 2012 Sep 13;489(7415):309-12
pubmed: 22885698
Leukemia. 2013 Nov;27(11):2196-9
pubmed: 23558524
Blood. 2009 Oct 22;114(17):3615-24
pubmed: 19690339
Blood. 2009 Jan 8;113(2):403-11
pubmed: 18948572
Blood. 2012 Mar 1;119(9):2106-9
pubmed: 22234701
Clin Cancer Res. 2012 Apr 1;18(7):1870-8
pubmed: 22322667
Haematologica. 2018 Apr;103(4):e158-e161
pubmed: 29269523
Methods Mol Biol. 2019;1956:139-155
pubmed: 30779034
Lancet Haematol. 2017 Mar;4(3):e114-e126
pubmed: 28257752
Leukemia. 2017 Jul;31(7):1477-1481
pubmed: 28439111
Mol Med. 2012 Dec 06;18:1281-91
pubmed: 22437326
Blood. 2005 Nov 15;106(10):3575-83
pubmed: 16076869
Clin Cancer Res. 2018 Oct 15;24(20):5048-5057
pubmed: 29945996
Haematologica. 2016 Sep;101(9):e369-73
pubmed: 27479817
Blood. 1999 Sep 15;94(6):1840-7
pubmed: 10477712
Cell. 2020 Jul 9;182(1):73-84.e16
pubmed: 32425270
Philos Trans R Soc Lond B Biol Sci. 2015 Sep 5;370(1676):
pubmed: 26194752
Haematologica. 2021 Apr 01;106(4):1178-1181
pubmed: 32586905
Blood. 1990 Aug 1;76(3):562-9
pubmed: 2378986
Leuk Lymphoma. 2015;56(11):3150-8
pubmed: 25860243
Br J Haematol. 2020 Jun;189(5):809-810
pubmed: 32002980
Mol Med. 2013 May 20;19:115-23
pubmed: 23615967
Clin Cancer Res. 2017 Sep 1;23(17):5292-5301
pubmed: 28536306
Haematologica. 2019 Dec 26;105(11):2598-2607
pubmed: 33131249
JCI Insight. 2017 Sep 7;2(17):
pubmed: 28878138
Science. 2009 Apr 10;324(5924):246-51
pubmed: 19251591
Leukemia. 2019 Feb;33(2):287-298
pubmed: 30555163
Leukemia. 2017 Feb;31(2):282-291
pubmed: 27811850
Cell. 2015 May 21;161(5):1026-1034
pubmed: 25959776
Semin Hematol. 2014 Jul;51(3):158-67
pubmed: 25048780
J Immunol. 2019 Dec 15;203(12):3095-3104
pubmed: 31818922
Blood. 2018 Jun 21;131(25):2745-2760
pubmed: 29540348
Science. 2011 Sep 16;333(6049):1593-602
pubmed: 21835983
Haematologica. 2016 Aug;101(8):959-67
pubmed: 27198719
Semin Cancer Biol. 2015 Oct;34:22-35
pubmed: 25963298
Nat Commun. 2017 Jun 09;8:15746
pubmed: 28598442
Blood. 2015 Jun 4;125(23):3580-7
pubmed: 25900981
Br J Haematol. 2009 Feb;144(4):492-506
pubmed: 19036101
Blood. 2012 May 10;119(19):4467-75
pubmed: 22415752
Int J Cancer. 2019 Jun 1;144(11):2695-2706
pubmed: 30447004
Methods Mol Biol. 2012;882:569-604
pubmed: 22665256
BMC Bioinformatics. 2018 Nov 20;19(Suppl 14):414
pubmed: 30453883
Blood. 2010 Jan 7;115(1):71-7
pubmed: 19887677
Leukemia. 2012 Jul;26(7):1638-46
pubmed: 22222599
Cell. 2016 Jul 28;166(3):609-623
pubmed: 27453470
Leukemia. 2010 Jan;24(1):125-32
pubmed: 19759557
Haematologica. 2010 Dec;95(12):2072-9
pubmed: 20801898
Blood. 2018 May 24;131(21):2283-2296
pubmed: 29666114
Blood. 2015 Jan 29;125(5):856-9
pubmed: 25634617
Science. 2011 Sep 16;333(6049):1633-7
pubmed: 21764753
Blood. 2008 Dec 15;112(13):5122-9
pubmed: 18812466
Leukemia. 2010 Jul;24(7):1317-24
pubmed: 20463750
Br J Haematol. 2014 Aug;166(4):621-5
pubmed: 24725250
Clin Cancer Res. 2009 Jul 1;15(13):4415-22
pubmed: 19509140
Am J Hematol. 2014 Jan;89(1):74-82
pubmed: 24030933
Leukemia. 2018 Jan;32(1):83-91
pubmed: 28592889
Blood Adv. 2020 Apr 14;4(7):1357-1366
pubmed: 32267931
Blood. 2011 Sep 15;118(11):3088-95
pubmed: 21791422
Mol Med. 2020 Mar 10;26(1):25
pubmed: 32156260
Epigenetics. 2012 Dec 1;7(12):1435-42
pubmed: 23154584
Proc Natl Acad Sci U S A. 2020 Feb 25;117(8):4320-4327
pubmed: 32047037
Leukemia. 2019 Jul;33(7):1801-1805
pubmed: 30679797
Haematologica. 2011 Nov;96(11):1644-52
pubmed: 21750087
Immunity. 2013 Aug 22;39(2):245-58
pubmed: 23911655
Mol Med. 2017 Mar;23:1-12
pubmed: 28097289
Blood. 2015 Apr 16;125(16):2497-506
pubmed: 25700432
Immunity. 2014 Dec 18;41(6):909-18
pubmed: 25526306
Immunity. 2000 Jul;13(1):37-45
pubmed: 10933393
J Clin Invest. 1998 Oct 15;102(8):1515-25
pubmed: 9788964
PLoS One. 2011;6(8):e24313
pubmed: 21897877
Haematologica. 2019 Feb;104(2):360-369
pubmed: 30262567
Blood. 2008 Feb 1;111(3):1524-33
pubmed: 17959859
J Clin Invest. 2005 Jun;115(6):1636-43
pubmed: 15902303
J Immunol. 2016 May 15;196(10):4410-7
pubmed: 27059597
Blood. 2010 May 13;115(19):3907-15
pubmed: 20110421
Lancet Haematol. 2014 Nov;1(2):e74-84
pubmed: 27030157
Blood. 2007 Jan 1;109(1):259-70
pubmed: 16985177
Blood. 1999 Sep 15;94(6):1848-54
pubmed: 10477713